F-star inks new licensing deal with Takeda

UK and USA-based biotech F-star Therapeutics, an invoX company, has entered into another collaboration with Japan’s largest drugmaker Takeda (TYO: 4502).

that it has entered into a strategic discovery collaboration and licence agreement with Takeda. The latest discovery and license agreement will leverage F-star’s proprietary fully-human Fcab and tetravalent monoclonal antibody (MAb²) platforms to research and develop next-generation multi-specific immunotherapies for patients with cancer.

Under the terms of the agreement, F-star and Takeda will jointly research and develop novel Fcab domains against undisclosed immuno-oncology targets. Takeda will receive a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize antibodies incorporating Fcab domains arising from the collaboration, and F-star will retain the right to research, develop, and commercialize antibodies incorporating certain other Fcab domains.